Meeting
2012 ASCO Annual Meeting
B-RAF mutation as a pejorative marker in metastatic melanoma.
Authors
Sophie Brissy
Hopital Timone, Aix-Marseille University, Marseille, France
Sophie Brissy , Caroline Gaudy-Marqueste , Stéphanie Mallet , Sandrine Monestier , Sylvie Hesse , Marie-Christine Koeppel , Marie-Christine Rojat-Habib , Isabelle Nanni , Anderson Loundou , L'houcine Ouafik , Nathalie Bonnet , Marie-Aleth Richard , Jean Jacques Grob
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8555)
DOI
10.1200/jco.2012.30.15_suppl.8555
Abstract #
8555
Poster Bd #
33E
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2020 ASCO Virtual Scientific Program
Metastases resection in colorectal cancer patients with mutation in oncogene BRAF or tumors located on the right side: Experience at the HGUGM.
First Author: Laura Ortega
Poster
2023 ASCO Annual Meeting
A powerful drug combination strategy targeting BRAF-mutant melanoma.
First Author: Luke Daniel Rothermel
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).
First Author: Jenny HJ Lee